Delving into the Latest Updates on P-7435 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

P 7435, P7435-DGAT1

Target

DGAT1

Action

inhibitors

Mechanism

DGAT1 inhibitors(Diacylglycerol O-acyltransferase 1 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes MellitusDiabetes Mellitus, Type 2Dyslipidemias+ [2]

Originator Organization

Piramal Phytocare Ltd.

Active Organization-

Inactive Organization

Piramal Phytocare Ltd.

Piramal Enterprises Ltd.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

* This is a single centre, phase I, randomized, double-blind, placebo-controlled, crossover, dose escalating study of P7435 using single and multiple doses, to be conducted in healthy male and female (Non child bearing) subjects having BMI between 19 to 40 kg/m2.
* The study will be conducted in 2 parts as follows: Part A will consist of the Single Ascending Dose (SAD) study and Part B will consist of the Multiple Ascending Dose (MAD) study.

Start Date01 Aug 2013

Sponsor / Collaborator

Piramal Enterprises Ltd.

[+1]

CTRI/2012/05/002691

/ TerminatedPhase 1

A phase I, randomized, double-blind, placebo-controlled study to determine the safety, tolerability, pharmacokinetics, food effect and pharmacodynamics of single and multiple ascending doses of P7435 in healthy, overweight and/or obese subjects

Start Date31 May 2012

Sponsor / Collaborator

Piramal Enterprises Ltd.

NCT01764425

/ TerminatedPhase 1

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight and/or Obese Subjects

Clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjects

Start Date01 May 2012

Sponsor / Collaborator

Piramal Enterprises Ltd.

100 Clinical Results associated with P-7435

Login to view more data

100 Translational Medicine associated with P-7435

Login to view more data

100 Patents (Medical) associated with P-7435

Login to view more data

100 Deals associated with P-7435

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 1	India	Piramal Enterprises Ltd.	01 May 2012
Diabetes Mellitus	Phase 1	United States	Piramal Enterprises Ltd.	-
Diabetes Mellitus	Phase 1	India	Piramal Enterprises Ltd.	-
Diabetes Mellitus, Type 2	Phase 1	-	Piramal Phytocare Ltd.	-
Dyslipidemias	Phase 1	-	Piramal Phytocare Ltd.	-
Lipid Metabolism Disorders	Phase 1	United States	Piramal Enterprises Ltd.	-
Lipid Metabolism Disorders	Phase 1	India	Piramal Enterprises Ltd.	-